| CAS |
No.116649-85-5 |
| 中文名称 |
雷马曲班 |
| 英文名称 |
Ramatroban |
| 别名 |
雷马曲班;CI-981;Atorvastatinhemicalcium;雷马曲班;BAY-U3405; |
| 分子式 |
C21H21FN2O4S |
| 分子量 |
416.47 |
| 溶解性 |
Soluble in DMSO ≥10mg/mL |
| 纯度 |
≥98% |
| 外观(性状) |
White to off-white Solid |
| 储存条件 |
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| 运输条件 |
冷藏运输 |
| MDL |
MFCD00887606 |
| SMILES |
O=C(O)CCN1C2=C(C3=C1C=CC=C3)C[C@H](NS(=O)(C4=CC=C(F)C=C4)=O)CC2 |
| InChIKey |
LDXDSHIEDAPSSA-OAHLLOKOSA-N |
| InChI |
InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1 |
| PubChem CID |
123879 |
| 靶点 |
thromboxaneA2 synthetase |
| 通路 |
Metabolic Enzyme&Protease |
| 背景说明 |
Ramatroban 是一种选择性血栓素 A2 (TxA2) 拮抗剂，可用于治疗过敏性鼻炎和哮喘的研究。 |
| 生物活性 |
Ramatroban is a selective thromboxane A2 (TxA2， IC50=14 nM) antagonist， which also antagonizes CRTH2 (IC50=113 nM) by inhibiting PGD2 binding.[1-3] |
| In Vitro |
Ramatroban is a potent human thromboxane receptor (hTP) antagonist with an IC50 of 18 nM in a human TP binding assay. Ramatroban inhibits prostaglandin D2 receptor DP2 (CRTH2) with an IC50 of 113 nM in a human DP2 binding assay. Ramatroban also inhibits human CYP isoform CYP2C9 with an IC50 of 15 μM[1]. Ramatroban is a selective thromboxane-type prostanoid (TP) receptor antagonist. PGD2-stimulated human eosinophil migration is shown to be mediated exclusively through activation of CRTH2， and surprisingly， these effects are completely inhibited by Ramatroban. Ramatroban is an antagonist for CRTH2， and inhibits PGD2-induced migration of eosinophils via CRTH2 blockade. 3H-labeled PGD2 binds to a single site on CRTH2 transfectants with high affinity (KD=6.3 nM， Bmax=450 pM). Nonlabeled PGD2 inhibits the binding of 3H-labeled PGD2 to CRTH2 transfectants in a concentration-dependent manner with an EC50 value of 2.7 nM. Ramatroban shows significant inhibitory effects on the binding of 3H-labeled PGD2 to CRTH2， albeit with much lower potency (IC50=100 nM). Ramatroban also inhibits PGD2-induced Ca2+ mobilization in CRTH2 transfectants to almost the same extent with an IC50 value of 30 nM. Ramatroban completely inhibits the PGD2-induced migration of eosinophils in a concentration-dependent manner with an IC50 value of 170 nM[2]. |
| In Vivo |
Ramatroban is an orally bioavailable small molecule antagonist of CRTH2. Systemic administration of Ramatroban (30 mg/kg) in CRTH2+/+ mice produces the same effects as seen in CRTH2 deficiency. Ramatroban completely blocks LPS-induced decreases in social and object exploratory behavior (p+/+ mice are completely reversed by a single injection of Ramatroban， even when the tumor is enlarged[3]. |
| 细胞实验 |
Human eosinophils are purified and resuspended in migration buffer (20 mM HEPES， pH 7.6， 0.1% BSA， Hanks solution) at a density of 6 ×106 cells/mL. Fifty microliters of the cell suspension (3×105 cells/well) is then dispensed into the upper chamber of a 96-well type chemotaxis chamber (pore diameter=5 μm)， and 30 μL of ligand solution is added to the lower chamber. Cells are preincubated with various concentrations of Ramatroban (0.1 nM， 1 nM， 10 nM， 100 nM， 1 μM and 10 μM) or BWA868C at 37°C for 10 min. The migration assays are performed in a humidified incubator at 37°C， 5% CO2 for 2 h. The number of cells migrating into the lower chamber is counted[2]. |
| 动物实验 |
Mice[3]
Five micrograms of LPS (closed columns) or saline (open columns) are intraperitoneally injected into CRTH2+/+ mice. CRTH2+/+ mice are pretreated intraperitoneally for 1 h with 30 mg/kg Ramatroban. |
| 激酶实验 |
CRTH2 transfectants are resuspended in binding buffer (50 mM Tris-HCl， pH 7.4， 40 mM MgCl2， 0.1% BSA， 0.1% NaN3). Cell suspension (2×105 cells)， 3H-labeled PGD2， and various concentrations of Ramatroban (0.1 nM， 1 nM， 10 nM， 100 nM， 1 μM and 10 μM) are then mixed in a 96-well U-bottomed polypropylene plate and incubated in a final volume of 100 μL for 60 min at room temperature. After incubation， the cell suspension is transferred to a filtration plate and washed three times with binding buffer. Scintillant is added to the filtration plate， and radioactivity remaining on the filter is measured by a scintillation counter. Nonspecific binding is determined by incubating the cell suspension and 3H-labeled PGD2 in the presence of 1 μM unlabeled PGD2[2]. |
| 数据来源文献 |
[1]. Stearns BA， et al. Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine modelof allergic rhinitis. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4647-51.
[2]. Sugimoto H， et al. An orally bioavailable small molecule antagonist of CRTH2， ramatroban (BAY u3405)， inhibits prostaglandin D2-induced eosinophil migration in vitro. J Pharmacol Exp Ther. 2003 Apr;305(1):347-52.
[3]. Haba R， et al. Central CRTH2， a second prostaglandin D2 receptor， mediates emotional impairment in the lipopolysaccharide and tumor-induced sickness behavior model. J Neurosci. 2014 Feb 12;34(7):2514-23. |
| 规格 |
1mg 5mg 10mg 25mg 50mg 100mg |
| 单位 |
瓶 |
中文
英语
说明书下载
京公网安备 11011202000391号